Mitochondrial Metabolism Linked to Acute Kidney Injury
BIDMC Contact: Jennifer Kritz Phone: 617-667-7301; Email: email@example.com
MARCH 16, 2016
Gene works through "aging molecule" to guard against stress; research offers new therapeutic target
BOSTON –Approximately one out of five hospitalized adults and one out of three hospitalized children worldwide experience acute kidney injury, the sudden loss of kidney function. Many different factors, including surgery, chemotherapy or shock, can lead to acute kidney injury, but exactly why the kidneys are so vulnerable to these and other stressors has not been well understood.
Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has discovered that mitochondria, the metabolic energy sources essential to the health of kidneys and other organs, also play a key role in kidney injury. The proof-of-concept study, published online today in the journal Nature, demonstrates that a gene called PGC1 alpha provides kidneys with protection by working through nicotinamide adenine dinucleotide (NAD), a molecule involved in metabolism thought to be key to the aging process.
The new findings suggest that manipulation of NAD could lead to a future therapy for acute kidney injury and also raise the possibility that mitochondrial injury and deficiency in NAD might underlie other kinds of organ damage, such as damage to the brain or heart, which can result in stroke or heart attack.
“Our laboratory has been working to understand the molecules and pathways that make the kidneys so vulnerable to so many stressors, including toxins and poor blood flow,” explained senior author Samir Parikh, MD, an investigator in the Division of Nephrology and in the Center for Vascular Biology Research (CVBR) at BIDMC and Associate Professor of Medicine at Harvard Medical School. “If we can understand the root of the problem, then we can work to make the kidney more robust in the face of these assaults.”
“Kidney injury is an enormous problem among hospitalized patients,” said nephrologist Mark Zeidel, MD, BIDMC Chair of Medicine. “Once patients develop acute kidney injury, their length of hospitalization increases, they command many more resources and, most saddening, their risk of mortality increases significantly. If we can prevent the onset of kidney injury we can potentially help many patients avoid life-threatening complications.”
The kidney is a highly metabolic organ that burns through mitochondrial “fuel” to generate adenosine triphosphate (ATP), the chemical energy that enables the kidney to filter blood and remove toxins from the body. “Within the kidney there is abundant ATP and mitochondria to carry out this essential chemical function.” said Parikh. “We hypothesized that mitochondria might also be serving as an essential and early target for the various risk factors leading to kidney injury.”
To test this hypothesis, a team led by first author Mei Tran, a senior scientist in the Parikh laboratory, began conducting studies of mitochondrial metabolism using microscopy, biochemistry and bioinformatics tools.
“We found that mitochondria were injured early and across different syndromes that were leading to kidney injury,” Tran said. “We next created mouse models genetically deficient in PGC1 alpha and the enzymes necessary to preserve mitochondrial function. As predicted, these models were found to have a greater-than-normal susceptibility to kidney injury.” On the flip side, said Tran, PGC1 alpha transgenic mice, which had increased expression of these genes, were particularly resistant to various stressors and recovered from injury much more than quickly than animals with normal regenerative abilities.
In collaboration with coauthors at Massachusetts General Hospital and the Broad Institute, the team went on to conduct a broad survey of metabolites within the kidney in order to examine chemical energy reactions in a number of different contexts – in the injured kidney, in the non-injured kidney and in genetically manipulated kidneys.
“One of the most robust reactions was a local deficiency of niacinamide [an analog of vitamin B3] within the injured kidney,” said Parikh. Vitamin B3 serves as a precursor for NAD, the ‘aging molecule’ at the heart of energy metabolism. “Recent studies have suggested that NAD levels fall with aging or with diabetes, which are two of the major risk factors for kidney injury. That was when a light bulb went on.”
To determine if increasing the level of NAD would accelerate recovery from kidney injury, the researchers administered extremely large quantities of vitamin B3 nutritional supplements – the human equivalent of hundreds of tablets –to the genetically impaired mice.
“We found that, following administration of the supplements, the kidneys were able to resist both toxic and ischemic stress,” said Parikh. “Normal doses of nutritional supplements are probably not going to cure kidney injury, but these experiments provide a proof-of-concept that metabolic manipulation of NAD might be a new avenue for the development of future therapies.
“Our work draws some new connections between PGC1 alpha and the NAD molecule, and their effects on metabolism,” added Parikh. “If indeed NAD levels fall with aging, the kidney may be a new window to thinking about how we study aging overall and may take us outside the world of acute injury to more broadly consider how the body deals with environmental stressors throughout life.”
Study coauthors include BIDMC investigators Zsuzsanna K. Zsengeller, Anders H. Berg, Eliyahu V. Khankin, Manoj K. Bhasin and Ananth Karumanchi; Wondong Kim and Eugene Rhee of Massachusetts General Hospital; and Clary B. Clish of the Broad Institute of MIT and Harvard.
This work was supported by NIH grants R01-DK095072; K08-DK090142; and K08-DK101560, as well as a grant from Satellite Healthcare.
About Beth Israel Deaconess Medical CenterBeth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org